Home » Topics » Nephrology, BioWorld Science

Nephrology, BioWorld Science
RSS

Synaptic discovers potent and selective human alpha1D-adrenoceptor antagonists

Feb. 24, 2000

Potent and selective alpha1D-adrenoceptor antagonists presented by Abbott

Feb. 18, 2000

Cortex receives notice of allowance for sexual dysfunction patent

Feb. 16, 2000

Preclinical studies support potential new indication for tamsulosin

Feb. 14, 2000

Kissei compounds display excellent beta3-adrenoceptor-stimulating effects

Feb. 11, 2000

Nastech claims formulations of sildenafil for nasal delivery

Feb. 11, 2000

Inhibitors of cGMP-PDEs under study at Bayer

Feb. 9, 2000

RenaGel receives marketing approval in the E.U.

Feb. 4, 2000

Edex/Viridal preferred, more efficacious than other ED therapies

Feb. 2, 2000

Patients prefer Invicorp over Caverject

Feb. 1, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...